These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 20499720)
1. The economic value of investing in regenerative medicine. Hussain A; Rivers PA J Health Care Finance; 2009; 36(2):45-54. PubMed ID: 20499720 [TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology guidance statement: the cost of cancer care. Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE; J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533 [TBL] [Abstract][Full Text] [Related]
3. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Mimeault M; Hauke R; Batra SK Clin Pharmacol Ther; 2007 Sep; 82(3):252-64. PubMed ID: 17671448 [TBL] [Abstract][Full Text] [Related]
4. Science and society: a stem cell technology model. Kiatpongsan S J Med Assoc Thai; 2008 Feb; 91(2):268-71. PubMed ID: 18389995 [TBL] [Abstract][Full Text] [Related]
5. [The industrialization of regenerative medicine--a potential market of $ 500 billion]. Gu Q; Zhang X; Jiang L Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Sep; 21(9):1011-5. PubMed ID: 17933243 [TBL] [Abstract][Full Text] [Related]
6. Regenerative medicine: a reality of stem cell technology. Terzic A; Edwards BS; McKee KC; Nelson TJ Minn Med; 2011 May; 94(5):44-7. PubMed ID: 21707014 [TBL] [Abstract][Full Text] [Related]
7. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine. Pangarkar N; Pharoah M; Nigam A; Hutmacher DW; Champ S Regen Med; 2010 Sep; 5(5):823-35. PubMed ID: 20868336 [TBL] [Abstract][Full Text] [Related]
8. Dual choice health insurance policy: a proposal and a cost analysis. Cheng J; Ives JC J Health Care Finance; 2009; 36(2):60-70. PubMed ID: 20499722 [TBL] [Abstract][Full Text] [Related]
9. Stem cells and regenerative medicine: principles, prospects and problems. Gardner RL C R Biol; 2007; 330(6-7):465-73. PubMed ID: 17631439 [TBL] [Abstract][Full Text] [Related]
10. New players enter field of regenerative medicine. Morrow T Manag Care; 2010 Sep; 19(9):48-9. PubMed ID: 20931895 [No Abstract] [Full Text] [Related]
11. Controlling America's health care costs via health care futures. Ray R Health Care Manage Rev; 1995; 20(2):85-91. PubMed ID: 7607890 [TBL] [Abstract][Full Text] [Related]
12. Prospects for translational regenerative medicine. Chen FM; Zhao YM; Jin Y; Shi S Biotechnol Adv; 2012; 30(3):658-72. PubMed ID: 22138411 [TBL] [Abstract][Full Text] [Related]
13. Policy roadmap for stem cell technology in Thailand. Kiatpongsan S J Med Assoc Thai; 2008 Jan; 91(1):124-8. PubMed ID: 18386556 [TBL] [Abstract][Full Text] [Related]
14. Confronting the challenges of long-term health care crisis in the United States. Hussain A; Rivers PA J Health Care Finance; 2009; 36(2):71-82. PubMed ID: 20499723 [TBL] [Abstract][Full Text] [Related]
15. Stemming the tide of health care costs. Ellis MS J La State Med Soc; 1991 Dec; 143(12):29-36. PubMed ID: 1779191 [TBL] [Abstract][Full Text] [Related]
16. Regenerative medicine and human models of human disease. Chien KR Nature; 2008 May; 453(7193):302-5. PubMed ID: 18480810 [TBL] [Abstract][Full Text] [Related]
18. [Adult stem cells and regenerative medicine: progress and prospect in some main fields]. Fu XB Zhonghua Yi Xue Za Zhi; 2007 May; 87(17):1153-5. PubMed ID: 17686229 [No Abstract] [Full Text] [Related]
19. The climbing costs of cancer care. Macready N J Natl Cancer Inst; 2011 Oct; 103(19):1433-5. PubMed ID: 21934075 [No Abstract] [Full Text] [Related]
20. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance. Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]